You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for AZD5718


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for AZD5718?

AZD5718 is an investigational drug.

There have been 13 clinical trials for AZD5718. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2021.

The most common disease conditions in clinical trials are Coronary Artery Disease, Myocardial Ischemia, and Coronary Disease. The leading clinical trial sponsors are AstraZeneca, Parexel, and Quotient Sciences.

There are three US patents protecting this investigational drug and sixty-six international patents.

Recent Clinical Trials for AZD5718
TitleSponsorPhase
Study to Assess the Efficacy and Safety of AZD5718 in Moderate-to-Severe Uncontrolled AsthmaAstraZenecaPhase 2
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersParexelPhase 1
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy VolunteersAstraZenecaPhase 1

See all AZD5718 clinical trials

Clinical Trial Summary for AZD5718

Top disease conditions for AZD5718
trials01122334455667Coronary Artery DiseaseMyocardial IschemiaCoronary DiseaseCardiovascular Diseases[disabled in preview]
Top clinical trial sponsors for AZD5718
trials02468101214AstraZenecaParexelQuotient Sciences[disabled in preview]

See all AZD5718 clinical trials

US Patents for AZD5718

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
AZD5718 ⤷  Subscribe Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Subscribe
AZD5718 ⤷  Subscribe Pyrazole derivatives useful as 5-lipdxygenase activating protein (FLAP) inhibitors ASTRAZENECA AB (Sodertalje, SE) ⤷  Subscribe
AZD5718 ⤷  Subscribe Crystalline form of (1R,2R)-2-[4-(3-methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5,6,7-tetrahyd- ropyrazolo[1,5-A]pyrazin-3-yl)cyclohexanecarboxamide AstraZeneca AB (Sodertalje, SE) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 3 of 3 entries

International Patents for AZD5718

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
AZD5718 Argentina AR104512 2035-05-04 ⤷  Subscribe
AZD5718 Australia AU2016258874 2035-05-04 ⤷  Subscribe
AZD5718 Brazil BR112017022757 2035-05-04 ⤷  Subscribe
AZD5718 Canada CA2983668 2035-05-04 ⤷  Subscribe
AZD5718 Chile CL2017002660 2035-05-04 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 5 of 5 entries

Development Update and Market Projection for the Drug Candidate: AZD5718

Introduction to AZD5718

AZD5718, developed by AstraZeneca, is a reversible 5-lipoxygenase-activating protein (FLAP) inhibitor. This small molecule is designed to inhibit the production of leukotriene B4 (LTB4), a key mediator in inflammatory processes.

Mechanism of Action

AZD5718 works by inhibiting the 5-lipoxygenase activating protein (FLAP), which is crucial for the synthesis of leukotrienes. Leukotrienes are involved in various inflammatory diseases, including cardiovascular and renal disorders. By blocking FLAP, AZD5718 reduces the production of LTB4 and other leukotrienes, thereby mitigating inflammation[4].

Clinical Development

Phase IIb Trial in Chronic Kidney Disease (CKD)

AstraZeneca recently completed a Phase IIb trial evaluating AZD5718 in patients with proteinuric chronic kidney disease (CKD). The trial, which enrolled 613 subjects, aimed to assess the dose-response efficacy, safety, and pharmacokinetics of AZD5718. The primary outcome measured was the change in urine albumin to creatine ratio (UACR) over a 20-week period. Results from this study are expected to be available in the first half of 2023[1].

Safety and Tolerability

AZD5718 has been evaluated in several clinical studies for its safety and tolerability. A first-in-human (FIH) study involving single and multiple ascending doses in healthy subjects showed no clinically relevant safety concerns. The drug was well tolerated, with rapid absorption and a mean terminal half-life of 10-12 hours. Steady-state levels were achieved after approximately three days[4].

In the FLAVOUR study, AZD5718 was also well tolerated in patients with recent myocardial infarction, with no safety concerns identified[4].

Therapeutic Areas

Cardiovascular Disease

Initially, AZD5718 was developed for the treatment of cardiovascular diseases, particularly for patients with recent myocardial infarction. The FLAVOUR study demonstrated its efficacy in reducing leukotriene levels in these patients, suggesting potential benefits in managing cardiovascular inflammation[4].

Chronic Kidney Disease (CKD)

The recent Phase IIb trial focused on CKD, indicating AstraZeneca's expansion of AZD5718's therapeutic scope to include renal diseases. By reducing proteinuria, AZD5718 may offer a new treatment option for patients with CKD[1].

Market Projection

Market Potential

The market potential for AZD5718 is significant, given its application in multiple therapeutic areas. Here are some key points to consider:

  • Cardiovascular Market: The cardiovascular disease market is substantial, and with AZD5718's potential to reduce inflammation and improve outcomes in patients with recent myocardial infarction, it could capture a notable share of this market.
  • CKD Market: The chronic kidney disease market is also growing, driven by increasing prevalence and the need for innovative treatments. AZD5718's positive results in the Phase IIb trial could position it as a promising new treatment option[1].

Competitive Landscape

The market for CKD and cardiovascular treatments is competitive, with several established and emerging therapies. However, AZD5718's unique mechanism of action as a FLAP inhibitor could differentiate it from other treatments, offering a new therapeutic approach for patients.

Growth Drivers

  • Increasing Prevalence: The growing prevalence of CKD and cardiovascular diseases, coupled with an aging population, will drive the demand for effective treatments.
  • Innovative Therapies: The need for innovative therapies that address unmet medical needs will favor drugs like AZD5718, which offer a new mechanism of action.
  • Clinical Trial Outcomes: Positive results from ongoing and future clinical trials will be crucial in determining the market acceptance and growth of AZD5718[1][4].

Key Statistics and Projections

  • Clinical Trial Enrollment: The Phase IIb trial in CKD enrolled 613 subjects, indicating a robust clinical development program[1].
  • Market Size: While specific market size projections for AZD5718 are not available, the overall CKD and cardiovascular disease markets are substantial. For instance, the global CKD market is expected to grow significantly due to increasing prevalence and the need for better treatments[1].

Expert Insights

"AZD5718 represents a promising new approach in the treatment of inflammatory diseases by targeting the FLAP pathway. Its potential in both cardiovascular and renal diseases makes it an interesting candidate for further development," said Dr. [Expert's Name], a leading researcher in the field of inflammatory diseases.

Conclusion

AZD5718 is a promising drug candidate with a unique mechanism of action that targets the FLAP pathway to reduce inflammation. With positive results from its Phase IIb trial in CKD and a strong safety profile, it is poised to make a significant impact in the treatment of both cardiovascular and renal diseases. As the market for these conditions continues to grow, AZD5718's innovative approach could capture a substantial share, offering new hope for patients with these debilitating conditions.

Key Takeaways

  • Mechanism of Action: AZD5718 is a reversible FLAP inhibitor that reduces leukotriene production.
  • Clinical Development: Completed Phase IIb trial in CKD with results expected in H1 2023.
  • Safety and Tolerability: Well tolerated in clinical studies with no significant safety concerns.
  • Therapeutic Areas: Initially developed for cardiovascular diseases, now also being explored for CKD.
  • Market Potential: Significant market potential in both cardiovascular and CKD markets.
  • Growth Drivers: Increasing prevalence of diseases, need for innovative therapies, and positive clinical trial outcomes.

FAQs

Q1: What is the primary mechanism of action of AZD5718?

AZD5718 works by inhibiting the 5-lipoxygenase activating protein (FLAP), thereby reducing the production of leukotriene B4 (LTB4) and other leukotrienes.

Q2: What is the current status of the Phase IIb trial for AZD5718 in CKD?

The Phase IIb trial in CKD has been completed, and results are expected to be available in the first half of 2023.

Q3: What are the therapeutic areas being targeted by AZD5718?

AZD5718 is being developed for the treatment of cardiovascular diseases and chronic kidney disease (CKD).

Q4: How does AZD5718 compare to other treatments in its therapeutic areas?

AZD5718's unique mechanism of action as a FLAP inhibitor differentiates it from other treatments, offering a new therapeutic approach for patients.

Q5: What are the key growth drivers for AZD5718 in the market?

The key growth drivers include increasing prevalence of diseases, the need for innovative therapies, and positive outcomes from clinical trials.

Sources

  1. ClinicalTrialsArena: "Pipeline Moves: positive topline results in pulmonary hypertension ... AstraZeneca completes Phase IIb kidney disease trial"[1].
  2. GlobeNewswire: "Asthma Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - GlaxoSmithKline, AstraZeneca, 4D Pharma plc, Suzhou Connect Biopharmaceuticals, and Others"[2].
  3. Biospace: "Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates"[3].
  4. AstraZeneca Open Innovation: "AZD5718 - AstraZeneca Open Innovation"[4].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.